Serotonin-noradrenalin reuptake inhibitors in the treatment of non-malignant pain syndromes; a systematic review;Serotonine-noradrenalineheropnameremmers bij chronische niet-maligne pijnsyndromen; een systematisch overzicht

Tijdschrift voor Psychiatrie

Volumn 51, Issue 11, 2009, Pages 831-840

  Vossen, H ^a   Monsieur, D ^b   Van Os, J ^a,c   Leue, C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Duloxetine; Pain; Venlafaxine

Indexed keywords

DULOXETINE; NORADRENALIN; SEROTONIN; VENLAFAXINE;

DIABETIC NEUROPATHY; FIBROMYALGIA; HUMAN; MASTECTOMY; NOCICEPTION; PAIN; REVIEW; SYSTEMATIC REVIEW;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; DIABETIC NEUROPATHIES; FIBROMYALGIA; HUMANS; PAIN; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 70549095128     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders (4de, herz. druk). Washington: American Psychiatric Association.
2. Armstrong, D.G., Chappell, A.S., Le, T.K., e.a. (2007). Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes. Pain Medicine, 8, 410-418.
3. Arnold, L.M., Lu, Y., Crofford, L.J., e.a. (2004). A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis & Rheumatism, 50, 2974-2984.
4. Arnold, L.M., Rosen, A., Pritchett, Y.L, e.a. (2005). A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain, 119, 5-15.
5. Brannan, S.K., Mallinckrodt, C.H., Brown, E.B., e.a. (2005). Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. Journal of Psychiatric Research, 39, 43-53.
6. Burckhardt, C.S., Clark, S.R., & Bennett, R.M. (1991). The Fibromyalgia Impact Questionnaire: development and validation. Journal of Rheumatology, 18, 728-733.
7. Carette, S., McCain, G.A., Bell, D.A., e.a. (1986). Evaluation of amitriptyline in primary fibrositis: a double-blind placebo-controlled study. Arthritis and Rheumatism, 29, 655-659.
8. Cleeland, C.S., & Ryan, K.M. (1994). Pain assessment: global use of the Brief Pain Inventory. The Annals of Academic Medicine Singapore, 23, 129-138.
9. Detke, M.J., Wiltse, C.G., Mallinckrodt, C.H., e.a. (2004). Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Neuropsychopharmacology, 14, 457-470.
10. Evren, B., Evren, C., & Guler, M.H. (2006). An open clinical trial of venlafaxine in the treatment of pain, depressive and anxiety symptoms in fibromyalgia. The Pain Clinic, 18, 167-173. (Pubitemid 43844626)
11. Goldstein, D.J., Lu, Y., Detke, M.J., e.a. (2005). Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain, 116, 109-118.
12. Häuser, W., Bernardy, K., Üçeyler, N., e.a. (2009) Treatment of fibromyalgia syndrome with antidepressants. JAMA, 301, 198-209.
13. Isomeri, R., Mikkelsson, M., Latikka, P., e.a. (1993). Effects of amitriptyline and cardiovascular fitness training on the patients with primary fibromyalgia. Journal of Musculatory Pain, 1, 253-260.
14. Jaeschke, R., Adachi, J., Guyatt, G., e.a. (1991). Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. Journal of Rheumatoloay, 18, 447-451.
15. Kempenaers, C., Simenon, G., Vander Elst, M., e.a. (1994). Effect of an antidiencephalon immune serum on pain and sleep in primary fibromyalgia. Neuropsychobiology, 30, 66-72.
16. Kind, P. (1996). The EuroQoL instrument: an index of health-related quality of life. In B. Spiker (Red.), Quality of life and pharmacoeconomics in clinical trials (2de druk). (pp. 191-201). Philadelphia: Lippincott-Raven.
17. Kroenke, K., Spitzer, R.L., & Williams, J.B. (2002). The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosomatic Medicine, 64, 258-266. (Pubitemid 34260463)
18. Kwaliteitsinstituut voor de Gezondheidszorg CBO (2007). Evidence-based richtlijnontwikkeling. Handleiding voor werkgroepleden. Utrecht: CBO.
19. Mallinckrodt, C.H., Clark, W.S., & David, S.R. (2001). Accounting for dropout bias using mixed-effects models. Journal of Biopharmacological Statistics, 11, 9-21.
20. Merskey, H., & Bogduk, N. (Red.). (1994). Classification of Chronic Pain (2de druk). (pp. 209-214). Seattle: IASP Press.
21. Price, D.D., McGrath, P.A., Rafii, A., e.a. (1983). The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain, 17, 45-56.
22. Pritchett, Y.L., McCarberg, B.H., Watkin, J.G., e.a. (2007). Duloxetine for the management of diabetic peripheral neuropathic pain: response profile. Pain Medicine, 8, 397-409.
23. Raskin, J., Smith, T.R., Wong, K., e.a. (2006a). Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. Journal of Palliative Medicine, 9, 29-40.
24. Raskin, J., Wang, F., Pritchett, Y.L., e.a. (2006b). Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Medicine, 7, 373-385.
25. Reuben, S.S., Makari-Judson, G., & Lurie, S.D. (2004). Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. Journal of Pain and Symptom Management, 27, 133-139. (Pubitemid 38221071)
26. Rowbotham, M.C., Goli, V., Kunz, N.R., e.a. (2004). Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain, 110, 697-706.
27. Sayar, K., Aksu, G., Ak, I., e.a. (2003). Venlafaxine treatment of fibromyalgia. The Annals of Pharmacotherapy, 37, 1561-1565.
28. Sindrup, S.H., Bach, F.W., Madsen, C., e.a. (2003). Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology, 60, 1284-1289.
29. Sir, A., D'Souza, R.F., Uguz, S., e.a. (2005). Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. Journal of Clinical Psychiatry, 66, 1312-1320.
30. Tasmuth, T., Härtel, B., & Kalso, E. (2002). Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain, 6, 17-24. (Pubitemid 34893790)
31. Wernicke, J.F., Pritchett, Y.L., D'Souza, D.N., e.a. (2006). A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology, 67, 1411-1420.
32. Wernicke, J.F., Wang, F., Pritchett, Y.L., e.a. (2007). An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Medicine, 8, 503-513.
33. Yucel, A., Ozyalcin, S., Koknel Talu, G., e.a. (2005). The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. European Journal of Pain, 9, 407-416.
34. Ziegler, D., Pritchett, Y.L., Wang, F., e.a. (2007). Impart of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care, 30, 664-669.